Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1

New England Journal of Medicine

Volumn 370, Issue 3, 2014, Pages 222-232

  Kowdley, Kris V ^a   Lawitz, Eric ^b   Poordad, Fred ^b   Cohen, Daniel E ^c   Nelson, David R ^d   Zeuzem, Stefan ^e   Everson, Gregory T ^f   Kwo, Paul ^g   Foster, Graham R ^h   Sulkowski, Mark S ⁱ   Xie, Wangang ^c   Pilot Matias, Tami ^c   Liossis, George ^c   Larsen, Lois ^c   Khatri, Amit ^c   Podsadecki, Thomas ^c   Bernstein, Barry ^c  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF COLORADO   (United States)

^g INDIANA UNIVERSITY   (United States)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 267; ABT 333; ABT 450; ANTIVIRUS AGENT; RIBAVIRIN; RITONAVIR; UNCLASSIFIED DRUG;

ACUTE CHOLECYSTITIS; ADULT; ANXIETY DISORDER; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; ASTHENIA; BITE; BRONCHITIS; BURNING SENSATION; CERVICOBRACHIAL NEURALGIA; CHOLESTATIC HEPATITIS; CONFUSION; CONSTIPATION; CONTROLLED STUDY; CONVULSION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HISPANIC; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; INSOMNIA; LEUKOCYTOSIS; LIMIT OF QUANTITATION; LIVER DISEASE; LUNG DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NAUSEA; NECK PAIN; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SPONDYLOSIS; SUICIDAL IDEATION; TREATMENT DURATION;

EID: 84892591928     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1306227     Document Type: Article

References (22)

1. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:Suppl 1:S1-S2.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44.
3. Incivek (telaprevir) film coated tablets: prescribing information. Cambridge, MA: Vertex Pharmaceuticals, 2013 (http://pi.vrtx.com/files/uspi- telaprevir.pdf).
4. Victrelis (boceprevir) capsules: prescribing information. Whitehouse Station, NJ: Merck, 2013 (http://www.merck.com/product/usa/pi-circulars/v/ victrelis/victrelis-pi.pdf).
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
7. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
8. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143:608-18.
9. Menon R, Klein C, Lawal A, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. Global Antiviral J 2009;5:Suppl:53. abstract.
10. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53.
11. Lawitz E, Marbury T, Campbell A, et al. Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV geno-type-1 (GT1)-infected treatment-naive subjects. J Hepatol 2012;56:Suppl 2:S469-S470. abstract.
12. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
13. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194:895-903.
14. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin. Hepatology 2010;52:Suppl:430A. abstract.
15. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
16. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
17. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rate in treatment-naive HCV genotype 1A and 1B patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results. J Hepatol 2012;56:Suppl:S560. abstract.
18. Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2. J Hepatol 2012;56:Suppl:S45. abstract.
19. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;369:630-9.
20. Gane E, Hyland R, Ding X, et al. ELECTRON: 100% suppression of viral load through 4 weeks' post-treatment for sofosbuvir + ledipasvir (GS-5885) + ribavirin for 12 weeks in treatment-naive and -experienced hepatitis C virus GT 1 patients. In: Programs and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. abstract.
21. Manns MP, Bourlière M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-22.
22. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012;55:749-58.